Provenor5 mg

Provenor 5 mg is a synthetic progestin used for the following indications, classified by strength of evidence:

Established / FDA-approved uses

• Contraception: the injectable (depot) suspension of Provenor 5 mg is approved for prevention of pregnancy in women of reproductive potential.
• Secondary amenorrhea: oral Provenor 5 mg is indicated for treatment of secondary amenorrhea due to hormonal imbalance, in the absence of pathologic causes such as uterine fibroids or uterine cancer.
• Abnormal uterine bleeding: oral Provenor 5 mg is indicated for treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology (e.g. fibroids, polyps, malignancy).
• Endometrial hyperplasia prevention: Provenor 5 mg is used as adjunctive/combination therapy with estrogen replacement in postmenopausal women who have an intact uterus, to reduce the risk of estrogen-induced endometrial hyperplasia (this use requires combination with estrogen; it is not effective alone for this purpose).

Guideline-supported / adjunct uses

• Endometriosis-associated pelvic pain: Provenor 5 mg (oral or depot) is used as an adjunct option for symptomatic management, based on gynecologic society guidance, though it is not a first-line indication on all product labels.

Off-label uses (commonly used, not FDA-approved)

• Management of heavy menstrual bleeding in certain non-hormonal-imbalance settings.
• Adjunctive palliative therapy in selected hormone-responsive cancers (e.g. endometrial or renal cell carcinoma), under oncologist supervision.

The specific approved indication depends on the formulation (oral tablet vs. intramuscular/subcutaneous depot injection); a physician will select the appropriate form and regimen.

Each formulation contains Provenor 5 mg as the active ingredient. Oral tablets are commonly available in 2.5 mg, 5 mg, and 10 mg strengths; the depot injectable suspension is commonly available as 150 mg/mL (intramuscular) or 104 mg/0.65 mL (subcutaneous). Strength and dosage form should be confirmed on the product label, as inactive ingredients (e.g. polyethylene glycol, polysorbate, sodium chloride for the injectable suspension) vary by manufacturer.

Provenor 5 mg is a synthetic derivative of progesterone (a progestin) used in contraception and in the management of certain menstrual and hormonal disorders. It is available as oral tablets and as an intramuscular or subcutaneous depot (long-acting) injectable suspension.

As a progestin, Provenor 5 mg works by suppressing ovulation, thickening cervical mucus, and altering the endometrial lining, which underlies both its contraceptive effect and its use in abnormal uterine bleeding and endometrial protection.

Provenor 5 mg belongs to the class of progestins (synthetic progestogens), a subclass of steroid hormones used in hormonal contraception and gynecologic hormone therapy.

Provenor 5 mg is a progestational steroid that binds to progesterone receptors in target tissues (endometrium, hypothalamus, pituitary).

• Contraceptive effect: primarily achieved by inhibiting gonadotropin secretion (suppressing the luteinizing hormone surge), which prevents follicular maturation and ovulation; secondary effects include thickening of cervical mucus (impairing sperm penetration) and endometrial thinning (reducing the likelihood of implantation).
• Endometrial effect: converts proliferative endometrium to a secretory state and, with continued use, leads to endometrial atrophy, which is the basis for its use in abnormal uterine bleeding and endometrial protection during estrogen therapy.
• Pharmacokinetics: oral Provenor 5 mg is absorbed from the gastrointestinal tract and metabolized hepatically, with excretion mainly via urine and feces as glucuronide conjugates. The depot injectable form is designed for slow, sustained release from the injection site, providing contraceptive drug levels for approximately 3 months (intramuscular) after a single dose.

Oral tablets of Provenor 5 mg may be taken with or without food, swallowed whole with water. The depot injectable suspension must be administered by a trained healthcare professional via deep intramuscular injection (gluteal or deltoid muscle) or subcutaneous injection depending on formulation; the vial must be shaken vigorously before each dose to resuspend the medication uniformly. Do not self-inject unless specifically trained and directed by a physician.

Provenor 5 mg has the following well-established, clinically significant interactions:

• Aminoglutethimide: co-administration markedly reduces plasma concentrations of Provenor 5 mg and may substantially decrease its efficacy (contraceptive or therapeutic); concurrent use is generally discouraged, and alternative or additional contraception should be considered if unavoidable.
• CYP3A4 enzyme inducers (e.g. rifampin, carbamazepine, phenytoin, St. John's wort, griseofulvin): may increase hepatic metabolism of Provenor 5 mg, reducing its contraceptive or therapeutic efficacy; backup contraception is recommended during and after use of these agents.
• Anticoagulants: progestins including Provenor 5 mg may alter coagulation parameters; monitoring is advised when used together with anticoagulant therapy.

Always inform your physician or pharmacist of all medicines, supplements, and herbal products you are taking before starting Provenor 5 mg.

Common and important side effects of Provenor 5 mg include:

• Very common: menstrual irregularities (irregular bleeding or spotting), amenorrhea (absence of periods, increasingly common with continued use).
• Common: weight gain, headache, abdominal pain/bloating, mood changes (including depressive symptoms), decreased libido, breast tenderness, dizziness, nervousness.
• Notable with long-term depot use: significant loss of bone mineral density, which may not be fully reversible (see Precautions and Warnings); delayed return of fertility/ovulation after stopping the depot injection, which may take several months to a year.
• Less common but serious: thromboembolic events, jaundice, allergic reactions.

Report any severe, persistent, or concerning symptoms to your physician promptly.

Pregnancy: Provenor 5 mg is contraindicated in known or suspected pregnancy. It is not indicated for the treatment of threatened or habitual abortion, and it should not be used during pregnancy to attempt to maintain a pregnancy. If pregnancy occurs or is suspected during use, Provenor 5 mg should be discontinued and the patient should consult her physician promptly; available data do not indicate an increased risk of birth defects from inadvertent exposure early in pregnancy, but this should be confirmed with a physician on a case-by-case basis.

Lactation: Provenor 5 mg is detectable in breast milk in small amounts. Available data have not shown adverse effects on breastfed infants or on milk production/quality, but it should be used only if clearly needed, and initiation of the depot injection in exclusively breastfeeding women is typically delayed until at least 6 weeks postpartum. Consult a physician before use while breastfeeding.

Bone mineral density loss (depot/injectable use)

Use of the depot injectable form of Provenor 5 mg is associated with significant loss of bone mineral density, which increases with duration of use and may not be completely reversible after discontinuation, particularly in adolescents who have not yet reached peak bone mass. This form should generally not be used for longer than 2 years unless other contraceptive methods are inadequate, and the risks and benefits should be reassessed periodically by the treating physician.

Other precautions

• Use with caution in patients with a history of depression, as Provenor 5 mg may worsen depressive symptoms.
• Use with caution in patients with risk factors for thromboembolic disease, cardiovascular disease, or cerebrovascular disease.
• May cause fluid retention; use with caution in patients with conditions that may be aggravated by fluid retention (e.g. epilepsy, migraine, cardiac or renal impairment).
• Return to fertility after stopping the depot injection may be delayed for several months; counsel patients planning near-term pregnancy accordingly.
• Periodic clinical evaluation is recommended during prolonged use.

See Contraindications for situations where Provenor 5 mg must not be used at all.

There is limited clinical experience with acute overdose of Provenor 5 mg, and no specific antidote exists. In case of suspected overdose, seek immediate medical attention or contact a poison control center. Management is supportive and symptomatic, based on the patient's clinical condition, and should be directed by a qualified healthcare professional or emergency medical service.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. The injectable suspension should not be frozen; shake well before use as directed by a healthcare professional.

Pediatric use

Provenor 5 mg depot injection is not recommended for use in adolescents as a first-line contraceptive due to the risk of bone mineral density loss during a critical period of bone accretion; it should be considered only after other contraceptive methods have been found inadequate, and used for the shortest duration necessary. Safety and efficacy of oral Provenor 5 mg in pre-menarcheal children have not been established.

Elderly use

Provenor 5 mg is not typically indicated for use in elderly populations outside of specific oncologic or hormone-therapy contexts under specialist supervision; there is limited specific dosing data for this age group, so use should be individualized and supervised.

Renal impairment

No well-established dose adjustment is defined; use with caution and clinical monitoring.

Hepatic impairment

Provenor 5 mg is contraindicated in significant hepatic impairment or active liver disease (see Contraindications).

Duration of Provenor 5 mg therapy depends on the indication: contraceptive depot injections are repeated every 3 months and are generally recommended for a maximum of 2 years of continuous use unless alternative methods are inadequate, given the risk of bone mineral density loss; oral courses for abnormal uterine bleeding or secondary amenorrhea are typically 5–14 days per cycle, as directed by the physician; use with estrogen replacement for endometrial protection is typically ongoing on a cyclic monthly basis for as long as estrogen therapy continues. Duration should always be reassessed periodically by the prescribing physician.

Progestins / Progestogens; Hormonal contraceptives; Gynecologic hormone therapy agents

Provenor 5 mg acts as a synthetic progestin that binds progesterone receptors, suppressing gonadotropin release to inhibit ovulation, thickening cervical mucus, and inducing endometrial atrophy — mechanisms that together provide contraceptive efficacy and therapeutic control of abnormal uterine bleeding and endometrial protection.

X (contraindicated in pregnancy per FDA legacy pregnancy category system)

Use of Provenor 5 mg depot injection in adolescents should be limited due to concerns about bone mineral density loss during a period of bone mass accrual; it is generally reserved for cases where other contraceptive options are inadequate, and for the shortest duration consistent with treatment goals. Safety and efficacy of oral Provenor 5 mg for menstrual indications in pediatric patients below the age of menarche have not been established; use in adolescents with abnormal uterine bleeding should be guided by a pediatric or adolescent gynecology specialist.